Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015

The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture their views on anticipated prescribing, reimbursement, and market access barriers in relation to current and emerging agents in prostate cancer. Five premium-priced therapies—Zytiga (Johnson & Johnson), Xtandi (Medivation), Provenge (Valeant), Xofigo (Bayer), and Jevtana (Sanofi)—are approved in the United States for prostate cancer, driving the metastatic castrate-resistant prostate cancer (mCRPC) market to become increasingly crowded and competitive. As novel therapies aim to enter this market, sequencing of treatments and gaining optimal reimbursement will be of increasing importance.

Contact sales account_box

Report

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…

north_east

Report

Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…

north_east

Report

Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

north_east

Report

Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…

north_east

Report

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)

Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…

north_east

Product logins

Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015

Related Market Assessment Reports

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)

Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)

Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)

Follow us

Contact us